File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety

TitleEffects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safety
Authors
Issue Date2006
PublisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/
Citation
Blood, 2006, v. 108 n. 1, p. 103-106 How to Cite?
AbstractVentricular tachyarrhythmias may occur during intravenous arsenic trioxide (As 2O 3). This has not happened during oral As 2O 3. Sixteen patients were studied by electrocardiography and 24-hour Holter monitoring at baseline, during and after oral As 2O 3 (As 2O 3-ON, As 2O 3-OFF). QT and corrected QT (QTc) were significantly longer during As 2O 3-ON than in As 2O 3-OFF, but QT and QTc dispersions were comparable. The patients' 24-hour heart rates were higher during As 2O 3-ON than in As 2O 3-OFF. QTc intervals at each hour were longer during As 2O 3-ON than in As 2O 3-OFF. However, QTc prolongation of more than 30 milliseconds only occurred at one time point (2 hours) after oral As 2O 3, resulting in QTc of more than 500 milliseconds in 3 of 16 patients, all within 4 hours of oral As 2O 3. Although the standard deviation of normal RR interval was lower during As 2O 3-ON, ratios of low frequency to high frequency power for As 2O 3-ON and As 2O 3-OFF were comparable. No ventricular proarrhythmias were observed. These observations, due to the lower peak plasma arsenic reached during oral As 2O 3, may explain the relative cardiac safety of oral As 2O 3. © 2006 by The American Society of Hematology.
Persistent Identifierhttp://hdl.handle.net/10722/162991
ISSN
2015 Impact Factor: 11.841
2015 SCImago Journal Rankings: 6.395
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSiu, CWen_US
dc.contributor.authorAu, WYen_US
dc.contributor.authorYung, Cen_US
dc.contributor.authorKumana, CRen_US
dc.contributor.authorLau, CPen_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2012-09-05T05:26:18Z-
dc.date.available2012-09-05T05:26:18Z-
dc.date.issued2006en_US
dc.identifier.citationBlood, 2006, v. 108 n. 1, p. 103-106en_US
dc.identifier.issn0006-4971en_US
dc.identifier.urihttp://hdl.handle.net/10722/162991-
dc.description.abstractVentricular tachyarrhythmias may occur during intravenous arsenic trioxide (As 2O 3). This has not happened during oral As 2O 3. Sixteen patients were studied by electrocardiography and 24-hour Holter monitoring at baseline, during and after oral As 2O 3 (As 2O 3-ON, As 2O 3-OFF). QT and corrected QT (QTc) were significantly longer during As 2O 3-ON than in As 2O 3-OFF, but QT and QTc dispersions were comparable. The patients' 24-hour heart rates were higher during As 2O 3-ON than in As 2O 3-OFF. QTc intervals at each hour were longer during As 2O 3-ON than in As 2O 3-OFF. However, QTc prolongation of more than 30 milliseconds only occurred at one time point (2 hours) after oral As 2O 3, resulting in QTc of more than 500 milliseconds in 3 of 16 patients, all within 4 hours of oral As 2O 3. Although the standard deviation of normal RR interval was lower during As 2O 3-ON, ratios of low frequency to high frequency power for As 2O 3-ON and As 2O 3-OFF were comparable. No ventricular proarrhythmias were observed. These observations, due to the lower peak plasma arsenic reached during oral As 2O 3, may explain the relative cardiac safety of oral As 2O 3. © 2006 by The American Society of Hematology.en_US
dc.languageengen_US
dc.publisherAmerican Society of Hematology. The Journal's web site is located at http://bloodjournal.hematologylibrary.org/en_US
dc.relation.ispartofBlooden_US
dc.subject.meshAdministration, Oralen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshArsenicals - Administration & Dosage - Blood - Therapeutic Useen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Toxicityen_US
dc.subject.meshElectrocardiographyen_US
dc.subject.meshElectrocardiography, Ambulatoryen_US
dc.subject.meshFemaleen_US
dc.subject.meshHeart Conduction System - Drug Effects - Physiopathologyen_US
dc.subject.meshHeart Rate - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Promyelocytic, Acute - Diagnosis - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOxides - Administration & Dosage - Blood - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleEffects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: Implications for long-term cardiac safetyen_US
dc.typeArticleen_US
dc.identifier.emailSiu, CW:cwdsiu@hkucc.hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.emailTse, HF:hftse@hkucc.hku.hken_US
dc.identifier.authoritySiu, CW=rp00534en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_OA_fulltexten_US
dc.identifier.doi10.1182/blood-2006-01-0054en_US
dc.identifier.pmid16514059-
dc.identifier.scopuseid_2-s2.0-33745613529en_US
dc.identifier.hkuros120313-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745613529&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume108en_US
dc.identifier.issue1en_US
dc.identifier.spage103en_US
dc.identifier.epage106en_US
dc.identifier.isiWOS:000238596900023-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridSiu, CW=7006550690en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.scopusauthoridYung, C=15770437000en_US
dc.identifier.scopusauthoridKumana, CR=7005112381en_US
dc.identifier.scopusauthoridLau, CP=7401968501en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridTse, HF=7006070805en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats